VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

Autor: Guido Bocci, Alfredo Falcone, Andrea Fontana, Luca Galli, Giulio Francia, Anna Solini, Paola Orlandi, T. Di Desidero, Elisa Biasco, Anna Fioravanti, Lisa Derosa, Romano Danesi, Bastianina Canu, Riccardo Marconcini
Rok vydání: 2013
Předmět:
Male
Vascular Endothelial Growth Factor A
Oncology
Cancer Research
medicine.medical_specialty
Antineoplastic Agents
Hormonal
Angiogenesis Inhibitors
Adenocarcinoma
Pharmacology
metronomic chemotherapy
prostate cancer
pharmacogenetics
Polymorphism
Single Nucleotide
Dexamethasone
Disease-Free Survival
polymorphism
Prostate cancer
Internal medicine
medicine
Humans
Progression-free survival
Antineoplastic Agents
Alkylating
Cyclophosphamide
Survival analysis
Aged
Aged
80 and over
Sulfonamides
Cyclooxygenase 2 Inhibitors
business.industry
Prostatic Neoplasms
Middle Aged
Prostate-Specific Antigen
medicine.disease
VEGF
Metronomic Chemotherapy
Genotype frequency
metronomic cyclophosphamide
Exact test
Prostate-specific antigen
Treatment Outcome
Celecoxib
Pharmacogenetics
Administration
Metronomic
Pyrazoles
Kallikreins
Translational Therapeutics
business
Zdroj: British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1038/bjc.2013.398
Popis: Background: No data are available on the pharmacogenetics of metronomic chemotherapy in prostate cancer. The aim of this study was to evaluate the association between VEGF-A sequence variants and prostate-specific antigen (PSA) progression, progression-free survival (PFS) and overall survival (OS), in advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide (CTX), celecoxib and dexamethasone. Methods: Forty-three patients were enrolled, and genomic DNA was extracted. VEGF-A gene SNPs (−2578A/C, −634C/G, +936C/T) were analysed using TaqMan PCR assays. Hardy–Weinberg equilibrium was tested for each SNP, and genetic effects were evaluated by Fisher's exact test. PFS and OS were analysed with GraphPad Prism software, using the product limit method of Kaplan and Meier, and comparing survival curves using both the log-rank test and the Gehan–Wilcoxon test. We used Bonferroni correction to account for multiple testing, and a two-tailed P-value of
Databáze: OpenAIRE
Externí odkaz: